Optimizing Intravenous Glucose Microdialysis with an Embedded System Controller

使用嵌入式系统控制器优化静脉葡萄糖微透析

基本信息

批准号：
7800572
负责人：
George Subrebost
金额：
$ 13.94万
依托单位：
INVIVOMON, INC.
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-01 至 2011-12-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7800572
关键词：
Accounting Adoption Antineoplastic Agents Area Attention Beds Biological Assay Blood Blood Glucose Blood Tests Blood specimen Buffers Calibration Cardiac Surgery procedures Catheters Cessation of life Chemotherapy-Oncologic Procedure Clinical Clinical Management Clinical Research Communication Computerized Medical Record Computers Controlled Study Convection Cost Savings Critical Care Critical Illness Development Devices Diagnostic Diffusion Dose Electronics FDA approved Failure Fluid Shifts Fluorouracil Future Glucose Goals Hospitals Hypoglycemia Infusion procedures Inpatients Insulin Intensive Care Units Intravenous Knowledge Laboratories Lead Length of Stay Licensing Manufacturer Name Marketing Measurement Measures Medical Device Medical center Membrane Methods Microdialysis Modeling Monitor Nurses Nursing Staff Optics Osmosis Outpatients Patients Performance Pharmaceutical Preparations Pharmacotherapy Phase Plague Problem Solving Process Protocols documentation Pump Reading Recovery Reference Values Research Ethics Committees Safety Small Business Innovation Research Grant Source Staff Work Load Surveys System Technology Testing Therapeutic Time Tracer Transport Process United States Universities Variant Veins Venous Venous blood sampling Wireless Technology Work base blood glucose regulation capillary chemotherapy commercialization cost glucose monitor glucose sensor improved in vivo interest meetings meter mortality nursing intervention physical process point of care product development public health relevance technological innovation

项目摘要

DESCRIPTION (provided by applicant): Invivomon, Inc. is a company developing in vivo monitoring technologies that will monitor blood glucose automatically through an intravenous (IV) line. The device will consist of a glucose sensor and a small on-board computer that will compensate for measurement errors, provide calibration, and glucose level warnings. With these improvements it will be possible to markedly enhance the accuracy of glucose blood level measurements for tight glucose control (TGC). The long term goal is to develop a 'Smart IV' that can be deployed in any patient requiring an IV and will be programmable to gauge glucose, drug, and metabolite levels (e.g., lactate). Phase I will focus on improving microdialysis probe inaccuracies with glucose measurements and developing an empirical model that will be uploaded to the embedded system controller. Combining this controller with the intravenous microdialysis probe will make it feasible to achieve Clinical Laboratory Improvement Act (CLIA) standards for glucose measurements (10% error or less) and allow safer management of TGC in the Intensive Care Unit. Specific aims include the development of a system capable of detecting dynamic variations in probe performance and providing an empirical model that will provide a correction factor to glucose values. Clinical studies of patients in the Intensive Care Unit are planned for Phase II. The annual cost savings after implementing TGC protocol is expected to be $2-$3 billion based on the 120,000 critical care beds in the U.S. alone. PUBLIC HEALTH RELEVANCE: Keeping glucose levels within a certain range in hospital settings (such as in the intensive care unit) has been shown to be beneficial by reducing complications and the likelihood of death. Invivomon Inc. is a company developing monitoring technologies that will track glucose levels in blood for hospital patients with an intravenous (IV) line. The long term goal is to develop a 'Smart IV' that can monitor glucose, drug, and metabolite levels.

描述（由申请人提供）：Invivomon, Inc. 是一家开发体内监测技术的公司，该技术将通过静脉 (IV) 管线自动监测血糖。该设备将由一个葡萄糖传感器和一个小型机载计算机组成，该计算机将补偿测量误差、提供校准和葡萄糖水平警告。通过这些改进，将有可能显着提高血糖水平测量的准确性，以实现严格的血糖控制 (TGC)。长期目标是开发一种“智能静脉注射”，可以部署在任何需要静脉注射的患者身上，并且可以通过编程来测量葡萄糖、药物和代谢物水平（例如乳酸）。第一阶段将重点关注改善微透析探针与葡萄糖测量的不准确性，并开发将上传到嵌入式系统控制器的经验模型。将该控制器与静脉微透析探针相结合，可以实现临床实验室改进法案 (CLIA) 的葡萄糖测量标准（误差不超过 10%），并允许在重症监护病房中更安全地管理 TGC。具体目标包括开发一种能够检测探头性能动态变化并提供经验模型的系统，该模型将为葡萄糖值提供校正因子。计划对重症监护室患者进行第二阶段临床研究。仅在美国就拥有 12 万个重症监护床位，实施 TGC 协议后预计每年可节省 2-30 亿美元的成本。公共卫生相关性：事实证明，在医院环境（例如重症监护病房）中将血糖水平保持在一定范围内可以减少并发症和死亡的可能性。 Invivomon Inc. 是一家开发监测技术的公司，该技术将通过静脉 (IV) 管线跟踪医院患者的血糖水平。长期目标是开发一种可以监测血糖、药物和代谢物水平的“智能静脉注射”。